Physician profile
Jong Moon
NPI 1760545925
$997.36
in general payments reported to CMS, 2019-2025
14 companies · $328 in 2025
The $328 reported for 2025 was more than what 77% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.18 · 2020: $96.76 · 2021: $65.43 · 2022: $82.30 · 2023: $189 · 2024: $217 · 2025: $328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $734.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $286.12 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $226.01 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $182.87 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.82 | 2023-2025 | Jardiance |
| Pfizer INC. | $38.78 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $27.46 | 2021 | |
| Hologic Sales and Service, LLC | $21.61 | 2025 | Aptima, Thinprep 2000 Processor |
| Merck Sharp & Dohme LLC | $18.18 | 2019 | |
| Exact Sciences Corporation | $18.02 | 2025 | Cologuard Collection Kit |
| Allergan, INC. | $17.17 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $15.90 | 2025 | Cobenfy |
| Abbvie INC. | $14.73 | 2025 | |
| Phathom Pharmaceuticals, INC. | $13.60 | 2025 | Voquezna |
| Glaxosmithkline, LLC. | $13.09 | 2024 | Arexvy, Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jong Moon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.